Ad is loading...
ACHV
Price
$4.52
Change
+$0.03 (+0.67%)
Updated
Dec 6 closing price
95 days until earnings call
GMAB
Price
$21.82
Change
-$0.03 (-0.14%)
Updated
Dec 6, 04:59 PM (EDT)
66 days until earnings call
Ad is loading...

ACHV vs GMAB

Header iconACHV vs GMAB Comparison
Open Charts ACHV vs GMABBanner chart's image
Achieve Life Sciences
Price$4.52
Change+$0.03 (+0.67%)
Volume$75.23K
CapitalizationN/A
Genmab A/S ADS
Price$21.82
Change-$0.03 (-0.14%)
Volume$19.09K
CapitalizationN/A
ACHV vs GMAB Comparison Chart
Loading...
ACHV
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ACHV vs. GMAB commentary
Dec 09, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACHV is a StrongSell and GMAB is a Buy.

COMPARISON
Comparison
Dec 09, 2024
Stock price -- (ACHV: $4.52 vs. GMAB: $21.81)
Brand notoriety: ACHV and GMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACHV: 67% vs. GMAB: 84%
Market capitalization -- ACHV: $154.41M vs. GMAB: $13.68B
ACHV [@Biotechnology] is valued at $154.41M. GMAB’s [@Biotechnology] market capitalization is $13.68B. The market cap for tickers in the [@Biotechnology] industry ranges from $489.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.71B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACHV’s FA Score shows that 0 FA rating(s) are green whileGMAB’s FA Score has 0 green FA rating(s).

  • ACHV’s FA Score: 0 green, 5 red.
  • GMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, ACHV is a better buy in the long-term than GMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACHV’s TA Score shows that 4 TA indicator(s) are bullish while GMAB’s TA Score has 5 bullish TA indicator(s).

  • ACHV’s TA Score: 4 bullish, 6 bearish.
  • GMAB’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, GMAB is a better buy in the short-term than ACHV.

Price Growth

ACHV (@Biotechnology) experienced а +2.49% price change this week, while GMAB (@Biotechnology) price change was +1.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.01%. For the same industry, the average monthly price growth was -2.68%, and the average quarterly price growth was +10.76%.

Reported Earning Dates

ACHV is expected to report earnings on Mar 13, 2025.

GMAB is expected to report earnings on Feb 12, 2025.

Industries' Descriptions

@Biotechnology (-1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($13.7B) has a higher market cap than ACHV($154M). ACHV YTD gains are higher at: 9.709 vs. GMAB (-31.501). GMAB has higher annual earnings (EBITDA): 6.97B vs. ACHV (-29.95M). GMAB has more cash in the bank: 17.3B vs. ACHV (42.9M). ACHV has less debt than GMAB: ACHV (9.85M) vs GMAB (987M). GMAB has higher revenues than ACHV: GMAB (19.8B) vs ACHV (0).
ACHVGMABACHV / GMAB
Capitalization154M13.7B1%
EBITDA-29.95M6.97B-0%
Gain YTD9.709-31.501-31%
P/E RatioN/A21.43-
Revenue019.8B-
Total Cash42.9M17.3B0%
Total Debt9.85M987M1%
FUNDAMENTALS RATINGS
ACHV vs GMAB: Fundamental Ratings
ACHV
GMAB
OUTLOOK RATING
1..100
618
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9956
PRICE GROWTH RATING
1..100
6281
P/E GROWTH RATING
1..100
10086
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACHV's Valuation (63) in the Biotechnology industry is in the same range as GMAB (67) in the null industry. This means that ACHV’s stock grew similarly to GMAB’s over the last 12 months.

ACHV's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GMAB (100) in the null industry. This means that ACHV’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's SMR Rating (56) in the null industry is somewhat better than the same rating for ACHV (99) in the Biotechnology industry. This means that GMAB’s stock grew somewhat faster than ACHV’s over the last 12 months.

ACHV's Price Growth Rating (62) in the Biotechnology industry is in the same range as GMAB (81) in the null industry. This means that ACHV’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's P/E Growth Rating (86) in the null industry is in the same range as ACHV (100) in the Biotechnology industry. This means that GMAB’s stock grew similarly to ACHV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACHVGMAB
RSI
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
59%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
68%
Momentum
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
65%
MACD
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
61%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
65%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
70%
Advances
ODDS (%)
N/A
Bullish Trend 7 days ago
64%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 5 days ago
67%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
68%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
73%
View a ticker or compare two or three
Ad is loading...
ACHV
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
GMAB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WDH1.13N/A
N/A
Waterdrop
LPSN0.90N/A
-0.01%
LivePerson
MKTX239.93-4.03
-1.65%
MarketAxess Holdings
ADX.X0.242209-0.005357
-2.16%
AdEx cryptocurrency
VET9.55-0.48
-4.79%
Vermilion Energy

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-0.18%
GNMSF - GMAB
58%
Loosely correlated
-6.53%
AXON - GMAB
47%
Loosely correlated
-0.30%
VIR - GMAB
39%
Loosely correlated
+4.77%
PGEN - GMAB
38%
Loosely correlated
+0.47%
CRSP - GMAB
38%
Loosely correlated
+5.70%
More